Graymatters
31 employees on LinkedIn · 3 known investors
GrayMatters Health develops Prism, an interventional psychiatry suite that uses fMRI-informed EEG digital biomarkers and self-neuromodulation to help patients regulate brain activity linked to conditions such as PTSD and depression. It is sold to psychiatry clinics to augment standard-of-care therapies.
Also known as GrayMatters Health
Investors · 3
Key figures
latest reportedHeadcountAug 202631
Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Frequently asked questions
- What does Graymatters do?
- GrayMatters Health develops Prism, an interventional psychiatry suite that uses fMRI-informed EEG digital biomarkers and self-neuromodulation to help patients regulate brain activity linked to conditions such as PTSD and depression. It is sold to psychiatry clinics to augment standard-of-care therapies.
- Who are Graymatters's investors?
- Graymatters's investors include J-Impact, Joyance Partners, J-Ventures.